Scabies: A clinical update

Aust Fam Physician. 2017;46(5):264-268.

Abstract

Background: Scabies is a common, yet neglected, skin disease. Scabies occurs across Australia, but most frequently in socioeconomically disadvantaged populations in tropical regions, including in remote Aboriginal and Torres Strait Islander communities. In temperate settings, the disease clusters in institutional care facilities.

Objective: The objective of this article is to provide updates on the clinical diagnosis and treatment approaches for scabies in Australia.

Discussion: Clinical examination remains the mainstay of diagnosis, although dermatoscopy is a useful adjunct. Scabies presents with severe itch and a papular rash, with a predilection for the hands, feet and genitalia. The distribution may be more widespread in infants and older people. Secondary bacterial infection is also common in patients with scabies. Crusted scabies is a rare but highly infectious variant. Topical permethrin is highly effective for individual treatment, but less practical for treatment of asymptomatic contacts and control of outbreaks. Oral ivermectin is a safe and effective alternative, and is now listed on the Pharmaceutical Benefits Scheme as a third-line treatment.

MeSH terms

  • Australia / epidemiology
  • Benzoates / pharmacology
  • Benzoates / therapeutic use
  • Coinfection
  • Communicable Diseases / diagnosis
  • Communicable Diseases / epidemiology
  • Humans
  • Ivermectin / pharmacology
  • Ivermectin / therapeutic use
  • Permethrin / pharmacology
  • Permethrin / therapeutic use
  • Public Health / methods
  • Scabies / diagnosis*
  • Scabies / drug therapy*
  • Scabies / epidemiology
  • Skin Diseases, Vesiculobullous / etiology
  • Toluidines / pharmacology
  • Toluidines / therapeutic use
  • Urticaria / etiology

Substances

  • Benzoates
  • Toluidines
  • Permethrin
  • Ivermectin
  • crotamiton
  • benzyl benzoate

Supplementary concepts

  • Papular urticaria